EGFR and non-small cell lung carcinoma: However, phase 2 clinical trials of osimertinib combined with bevacizumab vs. osimertinib alone as second-line targeted therapy for EGFR T790M-mutated NSCLC patients did not report a PFS benefit in the combination treatment arm [33, 34].